Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus.
Nakase
H
H
Yamamoto
S
S
Matsuura
M
M
Honzawa
Y
Y
Chiba
T
T
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003587:Cytomegalovirus; D006801:Humans; D000069285:Infliximab; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab; D016559:Tacrolimus